# VRTX catalysts: VERTEX PHARMACEUTICALS INC / MA PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/vrtx/catalysts

> VERTEX PHARMACEUTICALS INC / MA (VRTX) has 40 upcoming catalysts. The next is the povetacicept PDUFA date, November 30, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only, half-year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for VRTX?

VERTEX PHARMACEUTICALS INC / MA (VRTX) has 40 upcoming catalysts. The next is the povetacicept PDUFA date, November 30, 2026. Press release filed with the SEC (EX-99): "•The BLA submission for accelerated approval of povetacicept in IgAN is under priority review by the U.S. FDA, with an assigned PDUFA target action date of November 30, 2026." [Calendar and source filings](https://sec-api.dev/companies/vrtx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0000875320-26-000287, https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm (retrieved 2026-11-12). Last confirmed 2026-11-13. Cite: https://sec-api.dev/companies/vrtx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | VERTEX PHARMACEUTICALS INC / MA |
| Ticker | VRTX (Nasdaq) |
| SEC CIK | 875320 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/vrtx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 12, 2018 | [Symdeko (Copackaged) (ivacaftor; ivacaftor, tezacaftor) FDA approval](https://sec-api.dev/pdufa/ivacaftor-ivacaftor-tezacaftor) | VRTX |  | completed, approved | "NDA210491 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20180212, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product SYMDEKO (COPACKAGED) (IVACAFTOR; IVACAFTOR, TEZACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210491%22)) |
| August 7, 2018 | [Orkambi (ivacaftor; lumacaftor) FDA approval](https://sec-api.dev/pdufa/ivacaftor-lumacaftor) | VRTX |  | completed, approved | "NDA211358 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20180807, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product ORKAMBI (IVACAFTOR; LUMACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211358%22)) |
| October 21, 2019 | [Trikafta (Copackaged) (elexacaftor, ivacaftor, tezacaftor; ivacaftor) FDA approval](https://sec-api.dev/pdufa/elexacaftor-ivacaftor-tezacaftor-ivacaftor) | VRTX |  | completed, approved | "NDA212273 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20191021, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212273%22)) |
| September 24, 2020 | [Kalydeco (ivacaftor) label expansion decision](https://sec-api.dev/pdufa/ivacaftor) | VRTX |  | completed, approved | "NDA203188 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20200924, review_priority PRIORITY; sponsor_name VERTEX PHARMS; product KALYDECO (IVACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203188%22)) |
| December 21, 2020 | [Trikafta (Copackaged) (elexacaftor, ivacaftor, tezacaftor; ivacaftor) label expansion decision](https://sec-api.dev/pdufa/elexacaftor-ivacaftor-tezacaftor-ivacaftor) | VRTX |  | completed, approved | "NDA212273 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20201221, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212273%22)) |
| December 21, 2020 | [Symdeko (Copackaged) (ivacaftor; ivacaftor, tezacaftor) label expansion decision](https://sec-api.dev/pdufa/ivacaftor-ivacaftor-tezacaftor) | VRTX |  | completed, approved | "NDA210491 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20201221, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product SYMDEKO (COPACKAGED) (IVACAFTOR; IVACAFTOR, TEZACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210491%22)) |
| December 21, 2020 | [Kalydeco (ivacaftor) label expansion decision](https://sec-api.dev/pdufa/ivacaftor) | VRTX |  | completed, approved | "NDA203188 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20201221, review_priority PRIORITY; sponsor_name VERTEX PHARMS; product KALYDECO (IVACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203188%22)) |
| June 8, 2021 | [Trikafta (Copackaged) (elexacaftor, ivacaftor, tezacaftor; ivacaftor) label expansion decision](https://sec-api.dev/pdufa/elexacaftor-ivacaftor-tezacaftor-ivacaftor) | VRTX |  | completed, approved | "NDA212273 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20210608, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212273%22)) |
| September 2, 2022 | [Orkambi (ivacaftor; lumacaftor) label expansion decision](https://sec-api.dev/pdufa/ivacaftor-lumacaftor) | VRTX |  | completed, approved | "NDA211358 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20220902, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product ORKAMBI (IVACAFTOR; LUMACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211358%22)) |
| April 26, 2023 | [Trikafta (Copackaged) (elexacaftor, ivacaftor, tezacaftor; ivacaftor) FDA approval](https://sec-api.dev/pdufa/elexacaftor-ivacaftor-tezacaftor-ivacaftor) | VRTX |  | completed, approved | "NDA217660 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20230426, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217660%22)) |
| May 3, 2023 | [Kalydeco (ivacaftor) label expansion decision](https://sec-api.dev/pdufa/ivacaftor) | VRTX |  | completed, approved | "NDA207925 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20230503, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product KALYDECO (IVACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207925%22)) |
| October 31, 2023 | [Exagamglogene autotemcel FDA advisory committee meeting](https://sec-api.dev/pdufa/exagamglogene-autotemcel) | VRTX |  | completed | "On October 31, 2023, the committee will discuss and make recommendations on biologics license application (BLA) 125787 from Vertex Pharmaceuticals, Inc. for exagamglogene autotemcel (exa-cel)." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-october-31-2023-meeting-announcement-10312023)) |
| December 13, 2024 | [Orkambi (ivacaftor; lumacaftor) label expansion decision](https://sec-api.dev/pdufa/ivacaftor-lumacaftor) | VRTX |  | completed, approved | "NDA206038 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20241213, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product ORKAMBI (IVACAFTOR; LUMACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA206038%22)) |
| December 20, 2024 | [Vanzacaftor FDA approval](https://sec-api.dev/pdufa/vanzacaftor) | VRTX | people with CF 6 years of age and older | completed, approved | "On December 20, 2024, the U.S. Food and Drug Administration approved ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis in people 6 years and older who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator gene that is responsive to ALYFTREK." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532024000231/vrtx-20241220.htm)) |
| December 20, 2024 | [VERTEX PHARMACEUTICALS INC / MA label expansion decision](https://sec-api.dev/companies/vrtx/catalysts) | VRTX | 94 additional non-F508del CFTR mutations | completed, approved | "•On December 20, 2024, Vertex received FDA approval for the expanded use of TRIKAFTA in patients with 94 additional non-F508del CFTR mutations." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/ex-991_q42024.htm)) |
| December 20, 2024 | [Alyftrek (deutivacaftor; tezacaftor; vanzacaftor calcium) FDA approval](https://sec-api.dev/pdufa/deutivacaftor-tezacaftor-vanzacaftor) | VRTX | For the treatment of cystic fibrosis (CF) in patients 6 years of age and older | completed, approved | "Alyftrek \| vanzacaftor, tezacaftor, and deutivacaftor \| 12/20/2024 \| For the treatment of cystic fibrosis (CF) in patients 6 years of age and olderDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| December 20, 2024 | [Trikafta (Copackaged) (elexacaftor, ivacaftor, tezacaftor; ivacaftor) label expansion decision](https://sec-api.dev/pdufa/elexacaftor-ivacaftor-tezacaftor-ivacaftor) | VRTX |  | completed, approved | "NDA217660 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20241220, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217660%22)) |
| 2025 | [Povetacicept interim data readout](https://sec-api.dev/pdufa/povetacicept) | VRTX |  | scheduled | "Vertex expects to complete enrollment in the interim analysis cohort in 2025 and apply for potential accelerated approval in the U.S. after this cohort reaches 36 weeks of treatment, assuming a positive interim analysis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/ex-991_q42024.htm)) |
| January 30, 2025 | [JOURNAVX (suzetrigine) FDA approval](https://sec-api.dev/pdufa/suzetrigine) | VRTX | To treat moderate to severe acute painPress Release | completed, approved | "Journavx \| suzetrigine \| 1/30/2025 \| To treat moderate to severe acute painPress Release Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| February 4, 2025 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/ex-991_q42024.htm)) |
| May 5, 2025 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532025000171/ex-991_q12025.htm)) |
| May 22, 2025 | [Kalydeco (ivacaftor) label expansion decision](https://sec-api.dev/pdufa/ivacaftor) | VRTX |  | completed, approved | "NDA203188 SUPPL-41 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority PRIORITY; sponsor_name VERTEX PHARMS; product KALYDECO (IVACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203188%22)) |
| May 27, 2025 | [VX-993 primary completion](https://sec-api.dev/pdufa/vx-993) | VRTX | Acute Pain | completed | "NCT06619847 (A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-27 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06619847)) |
| 2H 2025 | [VERTEX PHARMACEUTICALS INC / MA interim data readout](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | scheduled | "•Vertex expects to complete enrollment in the interim analysis cohort of the Phase 3 portion of the AMPLITUDE trial of inaxaplin in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532025000171/ex-991_q12025.htm)) |
| July 7, 2025 | [Exa-cel primary completion](https://sec-api.dev/pdufa/exa-cel) | VRTX | Sickle Cell Disease; Hematological Diseases; Hemoglobinopathies | completed | "NCT03745287 (A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated; Results First Posted 2026-09-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03745287)) |
| August 4, 2025 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532025000213/ex-991_q22025.htm)) |
| late 2025 | [Povetacicept NDA/BLA submission](https://sec-api.dev/pdufa/povetacicept) | VRTX |  | scheduled | "— R&D pipeline continues to make progress: five programs in pivotal development and povetacicept Phase 3 IgAN trial full enrollment complete; on track to submit first module of povetacicept IgAN BLA to FDA by end of 2025 —" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532025000230/ex-991_q32025.htm)) |
| September 4, 2025 | [Elx/tez/iva primary completion](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | completed | "NCT05882357 (Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-04 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated; Results First Posted 2026-10-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05882357)) |
| November 3, 2025 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532025000230/ex-991_q32025.htm)) |
| November 13, 2025 | [Exagamglogene autotemcel primary completion](https://sec-api.dev/pdufa/exagamglogene-autotemcel) | VRTX | Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn | completed | "NCT03655678 (A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-11-13 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03655678)) |
| 1H 2026 | [Povetacicept interim data readout](https://sec-api.dev/pdufa/povetacicept) | VRTX |  | scheduled | "Vertex remains on track to release interim analysis data in the first half of 2026 and also complete the submission in the first" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/ex-991_q42025.htm)) |
| 1H 2026 | [Povetacicept trial start](https://sec-api.dev/pdufa/povetacicept) | VRTX | gMG | scheduled | "•Vertex expects to initiate a placebo-controlled, Phase 2 dose-ranging proof-of-concept study evaluating povetacicept for the treatment of gMG in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/ex-991_q42025.htm)) |
| January 29, 2026 | [Elx/tez/iva primary completion](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | completed | "NCT05153317 (Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-29 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05153317)) |
| February 12, 2026 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/ex-991_q42025.htm)) |
| March 27, 2026 | [Alyftrek (deutivacaftor; tezacaftor; vanzacaftor calcium) label expansion decision](https://sec-api.dev/pdufa/deutivacaftor-tezacaftor-vanzacaftor) | VRTX |  | completed, approved | "NDA218730 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20260327, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product ALYFTREK (DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218730%22)) |
| March 27, 2026 | [Trikafta (Copackaged) (elexacaftor, ivacaftor, tezacaftor; ivacaftor) label expansion decision](https://sec-api.dev/pdufa/elexacaftor-ivacaftor-tezacaftor-ivacaftor) | VRTX |  | completed, approved | "NDA217660 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20260327, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217660%22)) |
| May 4, 2026 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/ex-991_q12026.htm)) |
| 2H 2026 | [VERTEX PHARMACEUTICALS INC / MA interim data readout](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | scheduled | "•Vertex is on track to share interim results from the GALILEO study in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)) |
| July 20, 2026 | [Inaxaplin primary completion](https://sec-api.dev/pdufa/inaxaplin) | VRTX | Proteinuric Kidney Disease | completed | "NCT06794996 (Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-20 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06794996)) |
| August 3, 2026 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/ex-991_q22026.htm)) |
| late 2026 | [Povetacicept interim data readout](https://sec-api.dev/pdufa/povetacicept) | VRTX |  | scheduled | "•the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development, support regulatory filings, or accelerate regulatory approval, including our plans to complete the full submission for potential accelerated approval of povetacicept in IgAN in the first half of 2026 and to share data from the interim analysis of the Phase 2/3 clinical trial of inaxaplin in AMKD in late 2026 or early" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)) |
| late 2026 | [Inaxaplin interim data readout](https://sec-api.dev/pdufa/inaxaplin) | VRTX |  | scheduled | "Vertex expects to share data from the interim analysis in late 2026 or early 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/ex-991_q42025.htm)) |
| Sep to Dec 2026 | [Biological/vaccine topline data readout](https://sec-api.dev/pdufa/biological-vaccine) | VRTX | Type 1 Diabetes; Kidney Transplant | scheduled | "NCT06832410 (An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09-17 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06832410)) |
| September 16, 2026 | [Exa-cel topline data readout](https://sec-api.dev/pdufa/exa-cel) | VRTX | Sickle Cell Disease; Hematological Diseases; Hemoglobinopathies | completed | "NCT03745287 (A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated; Results First Posted 2026-09-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03745287?tab=results)) |
| September 2026 | [Biological/vaccine primary completion](https://sec-api.dev/pdufa/biological-vaccine) | VRTX | Type 1 Diabetes; Kidney Transplant | delayed | "NCT06832410 (An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09-17 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06832410)) |
| Oct 2026 to Jan 2027 | [Vx-121/tez/d-iva topline data readout](https://sec-api.dev/pdufa/vx-121-tez-d-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05444257 (A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05444257)) |
| October 15, 2026 | [Elx/tez/iva topline data readout](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | completed | "NCT05882357 (Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-04 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated; Results First Posted 2026-10-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05882357?tab=results)) |
| October 2026 | [Vx-121/tez/d-iva primary completion](https://sec-api.dev/pdufa/vx-121-tez-d-iva) | VRTX | Cystic Fibrosis | delayed | "NCT05444257 (A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05444257)) |
| November 2, 2026 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)) |
| November 30, 2026 | [Povetacicept PDUFA date](https://sec-api.dev/pdufa/povetacicept) | VRTX | immunoglobulin A nephropathy | scheduled | "•The BLA submission for accelerated approval of povetacicept in IgAN is under priority review by the U.S. FDA, with an assigned PDUFA target action date of November 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)) |
| early 2027 | [Inaxaplin interim data readout](https://sec-api.dev/pdufa/inaxaplin) | VRTX |  | scheduled | "Vertex expects to share data from the interim analysis in early 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/ex-991_q12026.htm)) |
| Jan to Apr 2027 | [JOURNAVX (suzetrigine) topline data readout](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06696443 (Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06696443)) |
| January 2027 | [JOURNAVX (suzetrigine) primary completion](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06696443 (Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06696443)) |
| Mar to Jun 2027 | [VX-993 topline data readout](https://sec-api.dev/pdufa/vx-993) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06619860 (Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06619860)) |
| March 2027 | [VX-993 primary completion](https://sec-api.dev/pdufa/vx-993) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06619860 (Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06619860)) |
| Apr to Jul 2027 | [Elx/tez/iva topline data readout](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05331183 (Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05331183)) |
| Apr to Jul 2027 | [JOURNAVX (suzetrigine) topline data readout](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT07231419 (Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07231419)) |
| April 2027 | [Elx/tez/iva primary completion](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05331183 (Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05331183)) |
| April 2027 | [JOURNAVX (suzetrigine) primary completion](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT07231419 (Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07231419)) |
| May to Aug 2027 | [JOURNAVX (suzetrigine) topline data readout](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06628908 (Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06628908)) |
| May 2027 | [JOURNAVX (suzetrigine) primary completion](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06628908 (Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06628908)) |
| Jun to Sep 2027 | [Exagamglogene autotemcel topline data readout](https://sec-api.dev/pdufa/exagamglogene-autotemcel) | VRTX | Sickle Cell Disease; Hydroxyurea Failure; Hydroxyurea Intolerance | scheduled | "NCT05329649 (Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05329649)) |
| Jun to Sep 2027 | [Exagamglogene autotemcel topline data readout](https://sec-api.dev/pdufa/exagamglogene-autotemcel) | VRTX | Beta-Thalassemia; Thalassemia; Hematologic Diseases | scheduled | "NCT05477563 (Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-09 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05477563)) |
| June 2027 | [Exagamglogene autotemcel primary completion](https://sec-api.dev/pdufa/exagamglogene-autotemcel) | VRTX | Sickle Cell Disease; Hydroxyurea Failure; Hydroxyurea Intolerance | scheduled | "NCT05329649 (Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05329649)) |
| June 2027 | [Exagamglogene autotemcel primary completion](https://sec-api.dev/pdufa/exagamglogene-autotemcel) | VRTX | Beta-Thalassemia; Thalassemia; Hematologic Diseases | scheduled | "NCT05477563 (Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-09 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05477563)) |
| Jul to Oct 2027 | [VX-407 topline data readout](https://sec-api.dev/pdufa/vx-407) | VRTX | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | scheduled | "NCT07161037 (Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07161037)) |
| July 2027 | [VX-407 primary completion](https://sec-api.dev/pdufa/vx-407) | VRTX | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | scheduled | "NCT07161037 (Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07161037)) |
| Sep to Dec 2027 | [Elx/tez/iva topline data readout](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT06460506 (Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06460506)) |
| September 2027 | [Elx/tez/iva primary completion](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT06460506 (Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06460506)) |
| Nov 2027 to Feb 2028 | [Exagamglogene autotemcel topline data readout](https://sec-api.dev/pdufa/exagamglogene-autotemcel) | VRTX | Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn | scheduled | "NCT05356195 (Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-14 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05356195)) |
| November 2027 | [Exagamglogene autotemcel primary completion](https://sec-api.dev/pdufa/exagamglogene-autotemcel) | VRTX | Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn | scheduled | "NCT05356195 (Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-14 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05356195)) |
| Dec 2027 to Mar 2028 | [Zimislecel topline data readout](https://sec-api.dev/pdufa/zimislecel) | VRTX | Diabetes Mellitus, Type 1; Impaired Hypoglycemic Awareness; Severe Hypoglycemia | scheduled | "NCT04786262 (A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04786262)) |
| Dec 2027 to Mar 2028 | [Povetacicept topline data readout](https://sec-api.dev/pdufa/povetacicept) | VRTX | Immunoglobulin A Nephropathy | scheduled | "NCT07890909 (A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-12-12 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07890909)) |
| December 2027 | [Povetacicept primary completion](https://sec-api.dev/pdufa/povetacicept) | VRTX | Immunoglobulin A Nephropathy | scheduled | "NCT07890909 (A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-12-12 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07890909)) |
| December 2027 | [Zimislecel primary completion](https://sec-api.dev/pdufa/zimislecel) | VRTX | Diabetes Mellitus, Type 1; Impaired Hypoglycemic Awareness; Severe Hypoglycemia | scheduled | "NCT04786262 (A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04786262)) |
| Jun to Sep 2028 | [VX-147 topline data readout](https://sec-api.dev/pdufa/vx-147) | VRTX | Proteinuric Kidney Disease | scheduled | "NCT05312879 (Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-06-02 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05312879)) |
| June 2028 | [VX-147 primary completion](https://sec-api.dev/pdufa/vx-147) | VRTX | Proteinuric Kidney Disease | scheduled | "NCT05312879 (Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-06-02 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05312879)) |
| Dec 2028 to Mar 2029 | [Povetacicept topline data readout](https://sec-api.dev/pdufa/povetacicept) | VRTX | Primary Membranous Nephropathy | scheduled | "NCT07204275 (Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07204275)) |
| December 2028 | [Povetacicept primary completion](https://sec-api.dev/pdufa/povetacicept) | VRTX | Primary Membranous Nephropathy | scheduled | "NCT07204275 (Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07204275)) |
| Jan to Apr 2029 | [VX-670 topline data readout](https://sec-api.dev/pdufa/vx-670) | VRTX | Myotonic Dystrophy Type 1 (DM1) | scheduled | "NCT06926621 (A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-01-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06926621)) |
| January 2029 | [VX-670 primary completion](https://sec-api.dev/pdufa/vx-670) | VRTX | Myotonic Dystrophy Type 1 (DM1) | scheduled | "NCT06926621 (A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-01-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06926621)) |
| Mar to Jun 2029 | [Povetacicept topline data readout](https://sec-api.dev/pdufa/povetacicept) | VRTX | Myasthenia Gravis, Generalized | scheduled | "NCT07501702 (A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-03-02 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07501702)) |
| March 2029 | [Povetacicept primary completion](https://sec-api.dev/pdufa/povetacicept) | VRTX | Myasthenia Gravis, Generalized | scheduled | "NCT07501702 (A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-03-02 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07501702)) |
| Jul to Oct 2029 | [Vnz/tez/d-iva topline data readout](https://sec-api.dev/pdufa/vnz-tez-d-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05844449 (Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-07-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05844449)) |
| July 2029 | [Vnz/tez/d-iva primary completion](https://sec-api.dev/pdufa/vnz-tez-d-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05844449 (Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-07-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05844449)) |
| Dec 2029 to Mar 2030 | [Povetacicept topline data readout](https://sec-api.dev/pdufa/povetacicept) | VRTX | Immunoglobulin A Nephropathy | scheduled | "NCT07807995 (A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-12-28 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07807995)) |
| December 2029 | [Povetacicept primary completion](https://sec-api.dev/pdufa/povetacicept) | VRTX | Immunoglobulin A Nephropathy | scheduled | "NCT07807995 (A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-12-28 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07807995)) |
| Jun to Sep 2030 | [Vx-121/tez/d-iva topline data readout](https://sec-api.dev/pdufa/vx-121-tez-d-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05422222 (Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-06-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05422222)) |
| June 2030 | [Vx-121/tez/d-iva primary completion](https://sec-api.dev/pdufa/vx-121-tez-d-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05422222 (Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-06-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05422222)) |

## Drugs

- [Biological/vaccine](https://sec-api.dev/pdufa/biological-vaccine): Type 1 Diabetes
- [Alyftrek (deutivacaftor; tezacaftor; vanzacaftor calcium)](https://sec-api.dev/pdufa/deutivacaftor-tezacaftor-vanzacaftor): For the treatment of cystic fibrosis (CF) in patients 6 years of age and older
- [Trikafta (Copackaged) (elexacaftor, ivacaftor, tezacaftor; ivacaftor)](https://sec-api.dev/pdufa/elexacaftor-ivacaftor-tezacaftor-ivacaftor): 
- [Elx/tez/iva](https://sec-api.dev/pdufa/elx-tez-iva): Cystic Fibrosis
- [Exa-cel](https://sec-api.dev/pdufa/exa-cel): Sickle Cell Disease
- [Exagamglogene autotemcel](https://sec-api.dev/pdufa/exagamglogene-autotemcel): Sickle Cell Disease, Beta-Thalassemia
- [Inaxaplin](https://sec-api.dev/pdufa/inaxaplin): Proteinuric Kidney Disease
- [Kalydeco (ivacaftor)](https://sec-api.dev/pdufa/ivacaftor): 
- [Symdeko (Copackaged) (ivacaftor; ivacaftor, tezacaftor)](https://sec-api.dev/pdufa/ivacaftor-ivacaftor-tezacaftor): 
- [Orkambi (ivacaftor; lumacaftor)](https://sec-api.dev/pdufa/ivacaftor-lumacaftor): 
- [Povetacicept](https://sec-api.dev/pdufa/povetacicept): igan, immunoglobulin a nephropathy, people with gmg, gmg, pmn, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- [JOURNAVX (suzetrigine)](https://sec-api.dev/pdufa/suzetrigine): moderate-to-severe acute pain, moderate-to-severe acute pain in adults, with moderate-to-severe acute pain, and it, people with moderate-to-severe acute pain, with moderate-to-severe acute pain, To treat moderate to severe acute painPress Release, Diabetic Peripheral Neuropathic Pain
- [Vanzacaftor](https://sec-api.dev/pdufa/vanzacaftor): people with cf 6 years of age and older, cf 6 years of age and older, cystic fibrosis in people 6 years and older
- [Vnz/tez/d-iva](https://sec-api.dev/pdufa/vnz-tez-d-iva): Cystic Fibrosis
- [Vx-121/tez/d-iva](https://sec-api.dev/pdufa/vx-121-tez-d-iva): Cystic Fibrosis
- [VX-147](https://sec-api.dev/pdufa/vx-147): Proteinuric Kidney Disease
- [VX-407](https://sec-api.dev/pdufa/vx-407): Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- [VX-670](https://sec-api.dev/pdufa/vx-670): Myotonic Dystrophy Type 1 (DM1)
- [VX-993](https://sec-api.dev/pdufa/vx-993): Acute Pain, Diabetic Peripheral Neuropathic Pain
- [Zimislecel](https://sec-api.dev/pdufa/zimislecel): Diabetes Mellitus, Type 1

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/vrtx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VRTX catalysts: VERTEX PHARMACEUTICALS INC / MA PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/vrtx/catalysts

```bibtex
@misc{secapidev_companies_vrtx_catalysts_20261116,
  title        = {VRTX catalysts: VERTEX PHARMACEUTICALS INC / MA PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/vrtx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_vrtx_catalysts_20261116","title":"VRTX catalysts: VERTEX PHARMACEUTICALS INC / MA PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/vrtx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
